目的 觀察血塞通注射液聯(lián)合地爾硫 治療慢性肺源性心臟病的臨床療效。方法 選取2014年1月—2015年1月?lián)P中市人民醫(yī)院呼吸內(nèi)科收治的慢性肺源性心臟病患者86例,隨機(jī)分為對(duì)照組和治療組,每組各43例。對(duì)照組在基礎(chǔ)治療上口服鹽酸地爾硫 片,1片/次,3次/d。治療組在對(duì)照組的治療基礎(chǔ)上靜脈滴注血塞通注射液,0.2 g加入5%葡萄糖注射液250 mL中,1次/d。兩組均連續(xù)治療14 d。觀察兩組的臨床療效,同時(shí)比較兩組治療前后血漿黏度、紅細(xì)胞壓積、二氧化碳分壓(PaCO₂)、氧分壓(PaO₂)的變化情況。結(jié)果 治療后,對(duì)照組和治療組的總有效率分別為72.09%、88.37%,兩組總有效率比較差異具有統(tǒng)計(jì)學(xué)意義(P< 0.05)。治療后,兩組血漿黏度、紅細(xì)胞壓積、PaCO₂均顯著降低,PaO₂顯著升高,同組治療前后差異有統(tǒng)計(jì)學(xué)意義(P< 0.05);且治療后治療組這些觀察指標(biāo)的改善程度優(yōu)于對(duì)照組,兩組比較差異具有統(tǒng)計(jì)學(xué)意義(P< 0.05)。結(jié)論 血塞通注射液聯(lián)合地爾硫 治療慢性肺源性心臟病臨床療效確切,可改善患者血液流變學(xué)和血?dú)夥治鱿嚓P(guān)指標(biāo),具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To observe the clinical effect of Xuesaitong Injection combined with diltiazem in treatment of chronic pulmonary heart disease. Methods Patients (86 cases) with chronic pulmonary heart disease in Department of Respiratory of People's Hospital of Yangzhong City from January 2014 to January 2015 were randomly divided into control and treatment groups, and each group had 43 cases. The patients in the control group were po administered with Diltiazem Hydrochloride Tablets on the basis of foundation treatment, 1 tablet/time, three times daily. The patients in the treatment group were iv administered with Xuesaitong Injection on the basis of the control group, 0.2 g Xuesaitong Injection added into 5% Glucose Injection 250 mL, once daily. The patients in two groups were treated for 14 d. After treatment, the efficacy was evaluated, and the changes of plasma viscosity, erythrocyte deposited, PaCO₂, and PaO₂ in two groups before and after treatment were compared. Results After treatment, the efficacies in the control and treatment groups were 72.09% and 88.37%, respectively, and there were differences between two groups (P < 0.05). After treatment, plasma viscosity, erythrocyte deposited, and PaCO₂ were significantly decreased, PaO₂ was significantly increased, and the difference was statistically significant in the same group (P < 0.05). These observational indexes in the treatment group were better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Xuesaitong Injection combined with diltiazem has clinical curative effect in treatment of chronic pulmonary heart disease, and can improve blood rheology and blood gas analysis related indicators, which has a certain clinical application value.